1. Home
  2. Global Antibiotic Research and Development Partnership’s Neonatal Sepsis Programme (GARDP) support
UK - Department of Health and Social Care (DHSC)

Global Antibiotic Research and Development Partnership’s Neonatal Sepsis Programme (GARDP) support

Last updated: 19/12/2023
Project disclaimer
Disclaimer: The data for this page has been produced from IATI data published by UK - Department of Health and Social Care (DHSC). Please contact them (Show Email Address) if you have any questions about their data.


A partnership to fund the development of new treatments for severe bacterial infections in neonates under GARDP’s Neonatal Sepsis Programme


The overall purpose of GARDP’s neonatal sepsis programme is to develop up to three new or improved treatments for newborns with severe bacterial infections by 2023. The activities funded under this programme will make an important contribution towards achieving these objectives by prioritising three work packages with the following focus: 1. Improve clinical management of neonatal sepsis This work package includes three key activities: completion of the global observational study; commencing clinical programme to develop a treatment to be used in place of the current WHO recommended empiric treatment, ampicillin and gentamicin for neonatal sepsis, and conducting clinical and laboratory capability strengthening in support of the clinical programme. 2. Developing new and improved treatments for multi drug-resistant infections in neonates This work package will aim to develop an effective and safe treatment for confirmed or highly suspected MDR-GN pathogens, including K. pneumoniae, or Acinetobacter spp., that is affordable and adapted for use in neonates. 3. Accelerating regulatory approval and access in high burden LMICs Through this work package, GARDP will work with WHO, pharmaceutical companies and regulatory authorities to ensure the newly developed treatments are globally accessible and that they are not ‘lost’ to resistance within a few years after their introduction. To achieve this, GARDP, in partnership with the relevant partner(s), will develop regulatory, public health and market access (including supply and distribution) strategies for any treatments developed.


The country, countries or regions that benefit from this Programme.
Developing countries, unspecified
Disclaimer: Country borders do not necessarily reflect the UK Government's official position.

Status Implementation

The current stage of the Programme, consistent with the International Aid Transparency Initiative's (IATI) classifications.

Programme Spend

Programme budget and spend to date, as per the amounts loaded in financial system(s), and for which procurement has been finalised.

Participating Organisation(s)

Help with participating organisations

Accountable:Organisation responsible for oversight of the activity

Extending: Organisation that manages the budget on behalf of the funding organisation.

Funding: Organisation which provides funds.

Implementing: Organisations implementing the activity.


Sector groups as a percentage of total Programme budget according to the OECD Development Assistance Committee (DAC) classifications.


A comparison across financial years of forecast budget and spend to date on the Programme.

Download IATI Data for GB-GOV-10-PDP_GARDP_NS

Programme data last updated on 19/12/2023